MLN8237 to Treat Children With Relapsed/Refractory Solid Tumors

NCT02444884 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

54

Enrollment

NETWORK

Sponsor class

Conditions

Unspecified Childhood Solid Tumor, Excluding CNS
Neuroblastoma

Interventions

DRUG: MLN8237

Sponsor

Children's Oncology Group

Collaborators

[object Object]